Pivotal bioVenture Partners (US) is based in San Francisco and aims to identify companies developing differentiated sciences from discovery to early clinical development with the potential to deliver transformative therapies.


Rob Hopfner
Managing Partner

Heather Preston
Managing Partner

Peter Bisgaard
Managing Partner

Ash Khanna
Venture Partner

Karoly Nikolich
Venture Partner


selected portfolio

Oculis, is a novel, patent protected, SNP eye-drop technology platform allows for the first time drug treatment of retinal diseases with topical eye drops.

Iterum Therapeutics is a clinical-stage pharmaceutical company dedicated to developing significantly differentiated anti-infectives aimed at combating the global crisis of multi-drug resistant (MDR) pathogens.

Inozyme Pharma is a biotechnology company developing new medicines to treat rare, debilitating, and life-threatening calcification disorders for which there are no adequate treatment options.

Karuna Therapeutics is a clinical-stage company targeting muscarinic cholinergic receptors for the treatment of psychosis and cognitive impairment across central nervous system (CNS) disorders.

Entasis Therapeutics is developing a portfolio of innovative cures for serious drug-resistant bacterial infections, a global health crisis affecting the lives of millions of patients.

OculisSutrovax is dedicated to develop a best-in-class pneumococcal conjugate vaccine that could potentially take over the market currently held by Prevanar 13, Pneumovax and Synflorix.

Bolt Biotherapeutics is a start-up with compelling technology from Dr. Engleman’s Lab at Stanford University, which demonstrated complete cures in numerous cancer models. The company is backed by strong life sciences investors and is early in its growth curve, seeking bright, highly motivated individuals that will be the company’s future leaders to help it further develop and bring to patients novel and curative biotherapies.

A clinical stage biopharmaceutical company with the goal of curing cancer by developing targeted alpha therapeutics. They see targeted alpha therapeutics as the next generation of radiation therapy. At Fusion, they are pushing the boundaries of science to create innovative cancer treatments. They believe that targeted alpha therapeutics represent the evolution of radiopharmaceuticals which holds great promise to improve the lives of patients with cancer.